1
|
Al-Sabri MH, Ammar N, Korzh S, Alsehli AM, Hosseini K, Fredriksson R, Mwinyi J, Williams MJ, Boukhatmi H, Schiöth HB. Fluvastatin-induced myofibrillar damage is associated with elevated ROS, and impaired fatty acid oxidation, and is preceded by mitochondrial morphological changes. Sci Rep 2024; 14:3338. [PMID: 38336990 PMCID: PMC10858229 DOI: 10.1038/s41598-024-53446-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Accepted: 01/31/2024] [Indexed: 02/12/2024] Open
Abstract
Previously, we showed that fluvastatin treatment induces myofibrillar damage and mitochondrial phenotypes in the skeletal muscles of Drosophila. However, the sequential occurrence of mitochondrial phenotypes and myofibril damage remains elusive. To address this, we treated flies with fluvastatin for two and five days and examined their thorax flight muscles using confocal microscopy. In the two-day fluvastatin group, compared to the control, thorax flight muscles exhibited mitochondrial morphological changes, including fragmentation, rounding up and reduced content, while myofibrils remained organized in parallel. In the five-day fluvastatin treatment, not only did mitochondrial morphological changes become more pronounced, but myofibrils became severely disorganized with significantly increased thickness and spacing, along with myofilament abnormalities, suggesting myofibril damage. These findings suggest that fluvastatin-induced mitochondrial changes precede myofibril damage. Moreover, in the five-day fluvastatin group, the mitochondria demonstrated elevated H2O2 and impaired fatty acid oxidation compared to the control group, indicating potential mitochondrial dysfunction. Surprisingly, knocking down Hmgcr (Drosophila homolog of HMGCR) showed normal mitochondrial respiration in all parameters compared to controls or five-day fluvastatin treatment, which suggests that fluvastatin-induced mitochondrial dysfunction might be independent of Hmgcr inhibition. These results provide insights into the sequential occurrence of mitochondria and myofibril damage in statin-induced myopathy for future studies.
Collapse
Affiliation(s)
- Mohamed H Al-Sabri
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Biomedical Center (BMC), Uppsala University, Husargatan 3, 751 24, Uppsala, Sweden.
- Department of Pharmaceutical Biosciences, Uppsala University, 751 24, Uppsala, Sweden.
| | - Nourhane Ammar
- Institut de Génétique Et Développement de Rennes (IGDR), Université de Rennes, CNRS, UMR6290, 35065, Rennes, France
| | - Stanislava Korzh
- Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga, 1006, Latvia
| | - Ahmed M Alsehli
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Biomedical Center (BMC), Uppsala University, Husargatan 3, 751 24, Uppsala, Sweden
- Faculty of Medicine, King Abdulaziz University and Hospital, Al Ehtifalat St., 21589, Jeddah, Saudi Arabia
| | - Kimia Hosseini
- Department of Pharmaceutical Biosciences, Uppsala University, 751 24, Uppsala, Sweden
| | - Robert Fredriksson
- Department of Pharmaceutical Biosciences, Uppsala University, 751 24, Uppsala, Sweden
| | - Jessica Mwinyi
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Biomedical Center (BMC), Uppsala University, Husargatan 3, 751 24, Uppsala, Sweden
| | - Michael J Williams
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Biomedical Center (BMC), Uppsala University, Husargatan 3, 751 24, Uppsala, Sweden
| | - Hadi Boukhatmi
- Institut de Génétique Et Développement de Rennes (IGDR), Université de Rennes, CNRS, UMR6290, 35065, Rennes, France
| | - Helgi B Schiöth
- Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Biomedical Center (BMC), Uppsala University, Husargatan 3, 751 24, Uppsala, Sweden.
| |
Collapse
|
2
|
Gentreau M, Rukh G, Miguet M, Clemensson LE, Alsehli AM, Titova OE, Schiöth HB. Response to the Comment on "The Effects of Statins on Cognitive Performance Are Mediated by Low-Density Lipoprotein, C-Reactive Protein, and Blood Glucose Concentrations". J Gerontol A Biol Sci Med Sci 2024; 79:glad253. [PMID: 37983124 DOI: 10.1093/gerona/glad253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2023] Open
Affiliation(s)
- Mélissa Gentreau
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Gull Rukh
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Maud Miguet
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Laura E Clemensson
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Ahmed M Alsehli
- King Abdulaziz University, Department of Physiology, Faculty of Medicine, Jeddah, Kingdom of Saudi Arabia
| | - Olga E Titova
- Medical Epidemiology, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Helgi B Schiöth
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| |
Collapse
|
3
|
Gentreau M, Rukh G, Miguet M, Clemensson LE, Alsehli AM, Titova OE, Schiöth HB. The Effects of Statins on Cognitive Performance Are Mediated by Low-Density Lipoprotein, C-Reactive Protein, and Blood Glucose Concentrations. J Gerontol A Biol Sci Med Sci 2023; 78:1964-1972. [PMID: 37431946 PMCID: PMC10613010 DOI: 10.1093/gerona/glad163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Indexed: 07/12/2023] Open
Abstract
Statins are widely used for cardiovascular disease prevention but their effects on cognition remain unclear. Statins reduce cholesterol concentration and have been suggested to provide both beneficial and detrimental effects. Our aim was to investigate the cross-sectional and longitudinal association between statin use and cognitive performance, and whether blood low-density lipoprotein, high-density lipoprotein, triglycerides, glucose, C-reactive protein, and vitamin D biomarkers mediated this association. We used participants from the UK biobank aged 40-69 without neurological and psychiatric disorders (n = 147 502 and n = 24 355, respectively). We performed linear regression to evaluate the association between statin use and cognitive performance and, mediation analysis to quantify the total, direct, indirect effects and the proportion meditated by blood biomarkers. Statin use was associated with lower cognitive performance at baseline (β = -0.40 [-0.53, -0.28], p = <.0001), and this association was mediated by low-density lipoprotein (proportion mediated = 51.4%, p = .002), C-reactive protein (proportion mediated = -11%, p = .006) and blood glucose (proportion mediated = 2.6%, p = .018) concentrations. However, statin use was not associated with cognitive performance, measured 8 years later (β = -0.003 [-0.11, 0.10], p = .96). Our findings suggest that statins are associated with lower short-term cognitive performance by lowering low-density lipoprotein and raising blood glucose concentrations, and better performance by lowering C-reactive protein concentrations. In contrast, statins have no effect on long-term cognition and remain beneficial in reducing cardiovascular risk factors.
Collapse
Affiliation(s)
- Mélissa Gentreau
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Gull Rukh
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Maud Miguet
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Laura E Clemensson
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Ahmed M Alsehli
- Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
| | - Olga E Titova
- Medical Epidemiology, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| | - Helgi B Schiöth
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden
| |
Collapse
|
4
|
Qadi HH, Bendary MA, Almaghrabi SY, Zaher MAF, Karami MM, Alsehli AM, Babateen O, Arbaeen AF, Burzangi AS, Bazuhair MA. Exploring the Therapeutic Potential of Apigenin in Obesity-Associated Fibrinolytic Dysfunction: Insights From an Animal Study. Cureus 2023; 15:e40943. [PMID: 37503477 PMCID: PMC10370825 DOI: 10.7759/cureus.40943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/24/2023] [Indexed: 07/29/2023] Open
Abstract
INTRODUCTION Obesity (Obe) is a chronic metabolic disorder usually complicated by impaired fibrinolytic activity. Apigenin (Api) is one of the flavonoids that have anti-adiposity effects. This study aimed to explore the therapeutic potential of Api in high-fat diet (HFD)-induced obese rats. METHODS Twenty-four Wistar adult male rats were randomly allocated into control group, supplemented with a normal pellet diet (NPD); Api group, supplemented with Api (10 mg/kg) for eight weeks; Obe group, obesity was induced by feeding HFD for eight weeks; and Obe/Api group, obese rats supplemented with Api for eight weeks. Body mass index (BMI), homeostatic model assessment of insulin resistance (HOMA-IR), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), total superoxide dismutase (t-SOD) activity, and plasminogen activator inhibitor-1 (PAI-1) were measured. RESULTS Compared to the control group, Obe group exhibited a significant increase in BMI, HOMA-IR, TNF-α, MDA, and PAI-1. These results were also associated with a significant decrease in serum t-SOD activity. Supplementation of Api alleviated the measured deteriorated parameters and ameliorated visceral adiposity in obese rats. CONCLUSION This study provides compelling evidence regarding a promising role for Api in ameliorating the impairment of fibrinolytic activity in an Obe animal model. The observed effects are likely mediated through Api's anti-obesity properties, as well as its indirect modulation of PAI-1, oxidative stress, and inflammation. Future clinical studies are recommended that may make benefit of the preclinical therapeutic use of apigenin in obesity-associated fibrinolytic dysfunctions.
Collapse
Affiliation(s)
- Hasan H Qadi
- Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| | - Mohamed A Bendary
- Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| | - Safa Y Almaghrabi
- Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| | | | - Mohamed M Karami
- Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| | - Ahmed M Alsehli
- Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| | - Omar Babateen
- Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, SAU
| | - Ahmad F Arbaeen
- Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, SAU
| | - Abdulhadi S Burzangi
- Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| | - Mohammed A Bazuhair
- Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU
| |
Collapse
|
5
|
Williams MJ, Alsehli AM, Gartner SN, Clemensson LE, Liao S, Eriksson A, Isgrove K, Thelander L, Khan Z, Itskov PM, Moulin TC, Ambrosi V, Al-Sabri MH, Lagunas-Rangel FA, Olszewski PK, Schiöth HB. The Statin Target Hmgcr Regulates Energy Metabolism and Food Intake through Central Mechanisms. Cells 2022; 11:cells11060970. [PMID: 35326421 PMCID: PMC8946516 DOI: 10.3390/cells11060970] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/09/2022] [Accepted: 03/10/2022] [Indexed: 02/04/2023] Open
Abstract
The statin drug target, 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), is strongly linked to body mass index (BMI), yet how HMGCR influences BMI is not understood. In mammals, studies of peripheral HMGCR have not clearly identified a role in BMI maintenance and, despite considerable central nervous system expression, a function for central HMGCR has not been determined. Similar to mammals, Hmgcr is highly expressed in the Drosophila melanogaster brain. Therefore, genetic and pharmacological studies were performed to identify how central Hmgcr regulates Drosophila energy metabolism and feeding behavior. We found that inhibiting Hmgcr, in insulin-producing cells of the Drosophila pars intercerebralis (PI), the fly hypothalamic equivalent, significantly reduces the expression of insulin-like peptides, severely decreasing insulin signaling. In fact, reducing Hmgcr expression throughout development causes decreased body size, increased lipid storage, hyperglycemia, and hyperphagia. Furthermore, the Hmgcr induced hyperphagia phenotype requires a conserved insulin-regulated α-glucosidase, target of brain insulin (tobi). In rats and mice, acute inhibition of hypothalamic Hmgcr activity stimulates food intake. This study presents evidence of how central Hmgcr regulation of metabolism and food intake could influence BMI.
Collapse
Affiliation(s)
- Michael J. Williams
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Ahmed M. Alsehli
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
- Faculty of Medicine, King Abdulaziz University and Hospital, Al Ehtifalat St., Jeddah 21589, Saudi Arabia
| | - Sarah N. Gartner
- Department of Biological Sciences, University of Waikato, Private Bag 3105, Hamilton 3240, New Zealand; (S.N.G.); (K.I.); (P.K.O.)
| | - Laura E. Clemensson
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Sifang Liao
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Anders Eriksson
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Kiriana Isgrove
- Department of Biological Sciences, University of Waikato, Private Bag 3105, Hamilton 3240, New Zealand; (S.N.G.); (K.I.); (P.K.O.)
| | - Lina Thelander
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Zaid Khan
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
- Department of Plant Protection Biology, Swedish University of Agricultural Sciences (SLU), Sundsvägen 14, 230 53 Alnarp, Sweden
| | - Pavel M. Itskov
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Thiago C. Moulin
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Valerie Ambrosi
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Mohamed H. Al-Sabri
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Francisco Alejandro Lagunas-Rangel
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
| | - Pawel K. Olszewski
- Department of Biological Sciences, University of Waikato, Private Bag 3105, Hamilton 3240, New Zealand; (S.N.G.); (K.I.); (P.K.O.)
| | - Helgi B. Schiöth
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, 751 24 Uppsala, Sweden; (M.J.W.); (A.M.A.); (L.E.C.); (S.L.); (A.E.); (L.T.); (Z.K.); (P.M.I.); (T.C.M.); (V.A.); (M.H.A.-S.); (F.A.L.-R.)
- Correspondence:
| |
Collapse
|
6
|
Alsehli AM, Rukh G, Clemensson LE, Ciuculete DM, Tan X, Al-Sabri MH, Williams MJ, Benedict C, Schiöth HB. Differential associations of statin treatment and polymorphism in genes coding for HMGCR and PCSK9 to risk for insomnia. FRONT BIOSCI-LANDMRK 2021; 26:1453-1463. [DOI: 10.52586/5039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 10/14/2021] [Accepted: 10/20/2021] [Indexed: 11/09/2022]
|